Dr. Rahul Baxi highlights that a new Rs 16,000-a-month weight-loss injection isn't a miracle solution without essential ...

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly ...

While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Through his X handler, Kamath revealed that he has been following the developments around Ozempic and GLP-1 drugs with some ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and ...

Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is ...

Jefferies isn’t sweating Eli Lilly’s slightly slimmer projections for its weight-loss drug Orfo, maintaining a spicy $1,020 ...

Mounjaro (Tirzepatide), a groundbreaking GLP-1 receptor agonist targeting GIP receptors, is now available in India for ...

Weight loss “wonder drug” Wegovy will cost Irish users around €220 a month as it is not currently availably under either the ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...